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Available online 8 February 2007Abstract—Foscarnet (phosphonoformate trisodium salt), an antiviral used for the treatment of HIV and herpes virus infections, also
acts as an activator or inhibitor of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1). Interaction of the drug with 11 CA
isozymes has been investigated kinetically, and the X-ray structure of its adduct with isoform I (hCA I-foscarnet complex) has been
resolved. The ﬁrst CA inhibitor possessing a phosphonate zinc-binding group is thus evidenced, together with the factors governing
recognition of such small molecules by a metalloenzyme active site. Foscarnet is also a clear-cut example of modulator of an enzyme
activity which can act either as an activator or inhibitor of a CA isozyme.
 2007 Elsevier Ltd. All rights reserved.Metalloenzyme inhibition constitutes a widely used
means for the regulation of enzymatic activity in a mul-
titude of physiologically relevant biological systems, with
important consequences for phenomena such as biosyn-
thetic reactions, signal transduction, secretion of electro-
lytes, ovulation, embryonic development, blastocyst
implantation, nerve growth, morphogenesis, apoptosis,
inﬂammation, angiogenesis, cancer invasion and metas-
tasis, tissue resorption and remodeling, bone remodeling,
arthritis, atherosclerosis, aneurysm, breakdown of
blood–brain barrier, etc.1–4 The binding of an inhibitor
molecule to the catalytic metal ion(s) leads to the reorga-
nization of the active site geometry, with generation of
enzyme-inhibitor adducts which are catalytically ineﬀec-
tive. Metalloenzyme inhibitors contain a metal-binding
function attached to a scaﬀold that interacts with the
remaining binding regions of the enzyme active site.1–40960-894X/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmcl.2007.01.113
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q Coordinates and structure factors are deposited within the Protein
Data Bank (PDB Accession code 2IT4).
* Corresponding author. Tel.: +39 055 457 3005; fax: +39 055 457
3385; e-mail: claudiu.supuran@uniﬁ.itMany of the most widespread metalloenzymes are zinc-
containing ones.1–4 The Zn(II) ion(s) present in such en-
zymes generally show a high aﬃnity for sulfur and/or
nitrogen-containing ligands, and as a consequence, most
such enzyme inhibitors contain zinc-binding groups
incorporating sulfur/nitrogen functionalities.1–4 Howev-
er, there are many examples of zinc-binding groups coor-
dinating the metal ion by means of oxygen atom(s), most
of which incorporate the carboxylate functionality.
Examples of the most common zinc-binding functions
contained in metalloenzyme inhibitors include quite het-
erogeneous chemical classes, such as carboxylates,
hydroxamates, thiols, phosphorus-based compounds
(phosphates/phosphonates), sulfonamides (and their
variants such as the sulfamates/sulfamides), sulfodii-
mines, etc.1–4 For metalloproteases (among which the
matrix metalloproteinases represent the best studied
case), usually the strongest inhibitors are the hydroxa-
mates, followed by the thiols (which are 20–50 times less
potent than the structurally related hydroxamates),
whereas the carboxylates/phosphonates are 100-2000
times less potent inhibitors compared to the correspond-
ing hydroxamates incorporating the same organic
scaﬀold.3,4
Table 1. Inhibition constants of foscarnet ðOOC PO23 Þ trisodium
salt, against 11 CA isozymes, hCA I, II, IV, VA, VB, VII, IX, XII,
mCA XIII, and hCA XIV (h, human; m, murine isoform), for the CO2
hydration reaction, at 20 C15
Isoform KI
e (mM)
hCA Ia 24.1
hCA IIb 14.2
hCA IVb 0.82
hCA VAb 41.7
hCA VBb 11.8
hCA VIb 1.81
hCA VIIb 0.56
hCA IXc 2.21
hCA XIIc 1.29
mCA XIIId 0.87
hCA XIVb 3.60
a Human cloned isozyme, preincubation of enzyme with inhibitor for
5 days at 4 C.
b Recombinant, human isoforms, preincubation of enzyme with
inhibitor for 15 min at room temperature.12
c Catalytic domain of the human, recombinant isozymes, preincuba-
tion of enzyme with inhibitor for 15 min at room temperature.14
dMurine, recombinant isoform, preincubation of enzyme with inhibi-
tor for 15 min at room temperature.14
e Errors were in the range of 3–5% of the reported values, from three
diﬀerent assays.
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the active site of zinc enzymes.5–7 Two types of interac-
tions have been observed so far in most zinc enzymes,
exempliﬁed here by the carbonic anhydrase (CA, EC
4.2.1.1): (i) substitution of the non-protein fourth zinc li-
gand (a hydroxide ion or water molecule) by the inhib-
itor, as anionic species, with formation of a tetrahedral
zinc adduct, and (ii) addition of the inhibitor to the met-
al coordination sphere, with generation of trigonal-bipy-
ramidal adducts, in which the metal ion within the
enzyme active site is coordinated in addition to the three
protein ligands (His94, 96, and 119 in the case of CAs)
by a water molecule and the anion inhibitor.5–7
As many CA isoforms amongst the 16 presently known
in vertebrates8,9 are quite stable enzymes, that easily
crystallize in complex with various classes of inhibitors,
whereas their active site geometry is also shared by
many other enzyme families which are more diﬃcult to
investigate,1–4 studying the detailed interactions between
such inhibitors and the CA active site may lead to novel
developments for the better understanding of the cata-
lytic/inhibition mechanism of metalloenzymes, and also
to the development of pharmaceutically valuable com-
pounds.1–9
In this paper, we report the interaction of the antiviral
drug foscarnet (phosphonoformate trisodium salt,
2O3P-COO
Æ3Na+) used for the treatment of herpes
and HIV infections10,11 with 11 CA isozymes, and the
X-ray crystal structure for the adduct of the drug with
the human isoform I, hCA I. Two reasons prompted us
to perform this study: (i) foscarnet contains two potential
zinc-binding groups (the phosphonate and the carboxyl-
ate one) which have not been investigated up to now in
detail (by means of X-ray crystallography) for the design
of metalloenzyme inhibitors. Furthermore, there is a
multitude of possible ways in which these two groups
(alone, or both of them) could coordinate a metal ion
from an enzyme active site (for example, the carboxylate
can act as a mono- or bidentate ligand against many met-
al ions; the same could be achieved by the PO23 moiety
present in this drug); (ii) in a previous work12 we showed
by means of kinetic stopped-ﬂow measurements that this
antiviral drug acts as an activator of isoform hCA I and
as a weak inhibitor of four other physiologically relevant
isozymes, i.e., CA II, IV, VA, and IX. It appeared thus of
interest to investigate in detail its interaction with all
catalytically eﬃcient CA isozymes (i.e., CA I–XIV) in or-
der to better understand how such enzymes bind small
molecule regulators of activity,12,13 which may act either
as activators or inhibitors, and which might lead to the
drug design of interesting modulators of enzyme
activity.12,13
Inhibition data against 11 CA isozymes, i.e., hCA I,
hCA II, hCA VII and mCA XIII (cytosolic forms; h
stands for human, m for murine isoform), hCA IV
(membrane-associated), hCA VA and hCA VB (mito-
chondrial), hCA VI (secreted in the saliva), and hCA
IX, hCA XII, and hCA XIV (transmembrane, tumor-as-
sociated isozymes in the case of CA IX and XII),14 with
foscarnet are shown in Table 1.15Data of Table 1 allow us to draw the following conclu-
sions regarding the interaction of these CA isozymes
with the phosphonate antiviral drug foscarnet: (i) four
isozymes are weakly inhibited by foscarnet, with inhibi-
tion constants in the range of 11.8–41.7 mM. These iso-
forms are hCA I, hCA II (cytosolic) and hCA VA/VB
(mitochondrial). It is interesting to note that as men-
tioned in our previous study,12a if foscarnet was preincu-
bated with hCA I for 15 min (which is the standard
procedure used for assaying CA inhibitors/activators)15
the compound acts as an eﬃcient hCA I activator, with
an activation constant KA of 12 lM (but is an inhibitor
of all other investigated CA isozymes). This was after all
not such a surprising result, considering the fact that
many weak acids incorporating phosphate/phosphonate
or carboxylate moieties act as eﬃcient buﬀers.12a How-
ever, as shown later in the paper, the X-ray crystal data
reported here showed foscarnet to bind to the metal ion
within the hCA I active site, a binding site typical for
CA inhibitors8,9,12 and not CA activators, which do
not directly bind to the metal ion, but to a diverse region
of the enzyme cavity and participate thereafter in the
proton shuttling between the enzyme active site and
the reaction medium.14,16,17 Thus, this ‘discrepancy’
between kinetic data12a and crystal structure prompted
us to investigate in detail the interaction of this isoform
(hCA I) with foscarnet. Thus, a longer incubation be-
tween the enzyme and the inhibitor, of the order of sev-
eral days (2–5 days) allowed us to measure an inhibition
constant of hCA I by foscarnet of 24.1 mM. This is a
clear-cut example of a molecule which may act either
as a CA activator as well as a CA inhibitor against the
same isoform. Some evidences that 4-methylimidazole
may act either as an activator or as an inhibitor for iso-
zyme hCA II were furnished recently by Silverman’s
group.17c By means of X-ray crystallography it has been
shown that this modulator of activity binds in the
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wild-type, zinc enzyme (similarly to other CA activa-
tors),13,17 whereas for the Co(II)-substituted CA II, by
means of 1H-NMR relaxivity measurements it has been
calculated that 4-methylimidazole is coordinated to the
metal ion (and thus acts as an inhibitor with an inhibi-
tion constant of around 200 mM),17c with a distance
between Co(II) and one nitrogen atom of the azole of
4.8 A˚.17c This is an unacceptably long distance for a
coordination bond, even within an enzyme active site,
and we appreciate that the inhibition data proposed by
Silverman’s group are artefactual, whereas it is clearly
established that 4-methylimidazole acts as a CA activa-
tor similarly to histamine, histidine or other such deriv-
atives investigated earlier by this group.13 In fact, most
CA inhibitors coordinated to Zn(II) ion in various CA
isozymes show a distance between the metal ion and
the inhibitor atom coordinated to it in a much shorter
range of 1.7–2.2 A˚.5–7
Thus, when hCA I and foscarnet were in contact for a
short period (15 min12a–3 h, data not shown), an en-
zyme-activator complex is formed, in which foscarnet
shuttles protons between the active site and the environ-
ment, presumably by its two protonatable moieties, the
carboxylate and phosphonate one, facilitating the
catalytic turnover of hCA I. In this way, the nucleophilic
species of the enzyme (with hydroxide as the fourth
Zn(II) ligand) is formed, which explains the activating
properties of the compound, similarly to those of
L-His, the ﬁrst activator for which the X-ray crystal
structure in adduct with hCA I was recently reported
by this group.17a It should be also mentioned that the
aﬃnity of foscarnet for the activator binding site in
the CA I active cavity is good, i.e., in the low micromo-
lar range (KA of 12 lM), whereas that of L-His is much
higher, of around 30 nM. However, it may be probable
that foscarnet binds in a similar way as L-His to the acti-
vator binding site within the hCA I cavity,17a but we
were unable to characterize this interaction by means
of X-ray crystallography due to the fact that when
hCA I crystals and foscarnet were incubated for shorter
periods (3 h–5 days), no formation of a crystallographi-
cally characterizable complex occurred.
When the enzyme and inhibitor were incubated for longer
periods in solution (3–5 days), a totally diﬀerent behavior
was observed, with foscarnet acting as a CA I inhibitor
(aﬃnity in the millimolar range, KI of 24.1 mM—see
Table 1). The X-ray crystallographic data presented later
in the text will thus resolve the apparent contradiction
raised by us above, and also explain this rather low aﬃn-
ity of foscarnet for hCA I; (ii) isozymes hCA VI (secreted
in the saliva), hCA IX, hCAXII, and hCAXIV were bet-
ter inhibited by this compound as compared to the
isoforms discussed above, with KIs in the range of 1.81–
3.60 mM. It should be mentioned that all these four
isoforms are extracellular ones, being either secreted (in
saliva or milk in the case of CA VI)1b or transmembrane
ones (CA IX, XII, and XIV) with the active site situated
outside the cell;14 (iii) foscarnet showed submillimolar
aﬃnity for three CA isozymes, i.e., hCA IV (membrane-
anchored), hCA VII and mCAXIII (cytosolic isozymes),with KIs in the range of 0.56–0.87 mM (Table 1). What is
indeed remarkable is the fact that although all these 11
isozymes have exactly the same coordination sphere of
the catalytically critical zinc ion (where inhibitors bind),
with three histidine residues (His94, 96, and 119) and a
water molecule/hydroxide ion,1,7,8,14 their aﬃnity for this
inhibitor varies by a factor of 75, if one considers the iso-
zyme which is the best inhibited (CA VII, KI of 0.56 mM)
and the one with the worst inhibition proﬁle, i.e., CAVA,
with aKI of 41.7 mM.Thus, even for this very small inhib-
itor, supplementary factors regulate the interaction be-
tween inhibitor and active site, in addition to the
coordination to the metal ion. For having a better view
of these phenomena we resolved the X-ray crystal struc-
ture of foscarnet complexed to hCA I.
The overall structure of the hCA I-foscarnet complex is
similar to that of the native enzyme.18 The global struc-
ture of the protein remained essentially unaltered by the
binding of this ligand, with an rmsd of 0.4 A˚ (both for
molecules A and B, see later in the text). The ﬁnal model
of the hCA I-foscarnet complex was constituted from
two independently reﬁned molecules in the asymmetric
unit (molecule A and molecule B), related by a transla-
tion operator. It contained a total of 4038 protein atoms
and 366 water molecules. Each molecule also contained
one Zn(II) ion within the active site, critical for activity
and binding of inhibitors. The thermal B factors were as
follows: mean B (for the entire adduct) of 18.80; B for
the main chains of 18.11; B for side chain and water
molecules of 19.46; B for the foscarnet molecule of
36.70 (with an occupancy of 90%). The ﬁrst four amino
acids in both molecules A and B were missing due to the
lack of electron density, as observed in other CA I X-ray
crystallographic structures reported earlier.18 The crys-
tallographic parameters and reﬁnement statistics are
shown in Table 2.19 Only molecule A of the asymmetric
unit will be discussed and is shown in Figures 1 and 2,
for the sake of simplicity.
Inspection of the electron density maps showed only one
molecule of foscarnet bound within the active site of
hCA I (Fig. 1). The inhibitor was found near the Zn(II)
ion, being coordinated to it and interacting with amino
acid residues nearby, more precisely with Thr199,
His200, and Leu198. The electron density of two water
molecules involved in the binding of foscarnet (i.e.,
Wat215 and 336) was also clearly observed in the density
maps (Fig. 1). Unexpectedly, foscarnet coordinated to
the Zn(II) ion by means of the phosphonate moiety,
and not the carboxylate one (Figs. 1 and 2). This is in
fact the ﬁrst example of a CA inhibitor incorporating
a phosphorus zinc-binding functionality investigated
by crystallography, although many such complexes are
available in PDB.24 Thus, one of the oxygen atoms of
the phosphonate moiety of foscarnet (O3, see the crys-
tallographic numbering in Fig. 2a) is coordinated to
the Zn(II) ion, at a distance of 1.73 A˚ (a short one as
usually the Zn–X distance in other CA inhibitors is of
the order of magnitude of 1.80–2.20 A˚).6,24 However,
all inhibitors reported up to now were monoanions
(for example RSO2NH
 derivatives),24 whereas
foscarnet binds to Zn(II) with the phosphonate group
Figure 1. 2Fo-Fc electron density map contoured at 1r level for
foscarnet bound within the hCA I active site and water molecules w215
and w336 involved in binding. The zinc ion, its three histidine ligands
(His94, 96, and 119) as well as amino acid residues 198–200 involved in
the binding of the inhibitor are also evidenced. Only molecule A of the
asymmetric unit is shown, for the sake of simplicity.
Table 2. Crystallographic parameters and reﬁnement statistics for the
hCA I-foscarnet adduct
Parameter Value
Crystal parameter
Space group P212121
Cell parameters
a 62.58A˚
b 69.51 A˚
c 120.44 A˚
a, b, c 90
Data collection statistics (20.0–2.0 A˚)
Temperature (K) 100
No. of total reﬂections 217,484
No. of unique reﬂections 36020
Completeness (%)a 97.4 (90.0)
hI/r(I)i 8.3 (2.03)
R-sym (%) 12.7
Reﬁnement statistics (20.0–2.0 A˚)
R-factor (%) 24.9
R-free (%)b 31.0
Rmsd of bonds from ideality (A˚) 0.014
Rmsd of angles from ideality () 1.53
Molecules/asymmetric unit 2
R-factor = R|Fo  Fc|/RFo; R-free calculated with 5% of data.
a Values in parentheses relate to the highest resolution shell (2.1–2.0).
bR-sym = RjIi  <I>|/RIi.
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Figure 2. (a) Crystallographic numbering of foscarnet. (b) Schematic
representation of the interactions between the inhibitor and the hCA I
active site amino acid residues involved in its recognition. Figures
represent distances in A˚. Only molecule A of the asymmetric unit is
shown, for the sake of simplicity.
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additional electrostatic attraction between the positively
charged dication (Zn2+) and the negatively charged
dianion, with the consequent reduction of the Zn–O dis-
tance. Another oxygen atom of the phosphonate moiety
(O1) is hydrogen bonded to the backbone NH of
Thr199, an amino acid critically important for CA catal-
ysis/inhibition, with a distance of 2.77 A˚ between the
two atoms, whereas the third oxygen of this functional-
ity, O2, participates in two weaker hydrogen bonds, one(of 3.5 A˚) with the NH of His200, and the second one
(of 3.3 A˚) with a water molecule (Wat330) (Figs. 1 and
2b). It should be also mentioned that in all other CA
inhibitor adducts investigated up to now by means of
X-ray crystallography, the OH moiety of Thr199 was
observed to make a strong hydrogen bond to the X
inhibitor atom directly coordinated to the Zn(II) ion
in the Zn–X complex. However, in this case no such
bond was evidenced, as the distance between the
Thr199 OH and the O3 atom of foscarnet is of 3.88 A˚
(the distance between O1 of foscarnet and the same
OH moiety of Thr199 is on the other hand of 3.76 A˚,
and again no hydrogen bond is formed). The carboxyl-
ate moiety of foscarnet also interacts with a water mol-
ecule (hydrogen bond between O4 and Wat336 of 3.0 A˚)
and an amino acid residue in the vicinity of the zinc ion,
i.e., Leu198. However, this is a repulsive interaction, as
one methyl group of the side chain of Leu198 clashes
with the O5 atom of foscarnet, the two groups being
at a distance of only 2.86 A˚ (Fig. 2b). This phenomenon
was already reported earlier by us for other CA inhibi-
tors,25 and may explain why foscarnet is a relatively
weak CA I inhibitor (and also lead to the design of iso-
zyme-selective inhibitors), with a KI of around 24 mM
(however, much stronger as compared to 4-methylimi-
dazole, claimed by Silverman’s group to act either as
an activator, as well as an inhibitor of CA II, with a
KI of around 200 mM).
17c On the other hand, only
hCA I has the bulky His200 and thus a rather con-
strained active site cavity near the Zn(II) ion, which
may explain why other CA isoforms show much better
inhibition (up to 75-fold times) with this compound, as
compared to hCA I (Table 1).
In conclusion, we report here the ﬁrst X-ray crystal
structure of a compound possessing a phosphonate
zinc-binding group in complex with a metalloenzyme,
hCA I. The hCA I-foscarnet adduct data reported here
may be relevant for better understanding the interac-
tions between small molecules and metalloenzymes’
2214 C. Temperini et al. / Bioorg. Med. Chem. Lett. 17 (2007) 2210–2215active sites. Foscarnet is also the ﬁrst clear-cut example
of modulator of an enzyme activity which can act either
as an activator or inhibitor of a CA isozyme.Acknowledgment
This research was ﬁnanced in part by a 6th Framework
Programme of the European Union (EUROXY
project).References and notes
1. (a)Enzymes and their Inhibition—Drug Development;
Smith, H. J., Simons, C., Eds.; CRC Press: Boca Raton,
London, NewYork, 2005; p 1; (b)Carbonic Anhydrase—Its
Inhibitors and Activators; Supuran, C. T., Scozzafava, A.,
Conway, J., Eds.; CRC Press: Boca Raton (FL), USA,
2004; p 1, and references cited therein.
2. (a) Babine, R. E.; Bender, S. L. Chem. Rev. 1997, 97, 1359;
(b)Handbook of Proteolytic Enzymes; Barrett, A. J., Raw-
lings,N.D.,Woessner, J. F., Eds.; Academic Press: London
(CD-ROM), 1998, references cited therein; (c) Guo, H.;
Rao,N.; Xu, Q.;Guo,H. J. Am.Chem. Soc 2005, 127, 3191;
(d) Shin, H.; Cama, E.; Christianson, D. W. J. Am. Chem.
Soc 2004, 126, 10278; (e) Di Costanzo, L.; Flores, L. V., jr.;
Christianson, D. W. Proteins 2006, 65, 637.
3. (a) Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J.
H. Chem. Rev 1999, 99, 2735; (b) Leung, D.; Abbenante,
G.; Fairlie, D. P. J. Med. Chem. 2000, 43, 305; (c)
Supuran, C. T.; Scozzafava, A. Matrix metalloproteinases
(MMPs). In Proteinase and Peptidase Inhibition: Recent
Potential Targets for Drug Development; Smith, H. J.,
Simons, C., Eds.; Taylor & Francis: London, New York,
2002; p 35; (d) Temperini, C.; Innocenti, A.; Scozzafava,
A.; Supuran, C. T. Bioorg. Med. Chem. Lett. 2006, 16,
4316; (e) Chin, D. N.; Lau, A. Y.; Whitesides, G. M.
J. Org. Chem. 2005, 63, 938.
4. (a) Grams, F.; Crimmin, M.; Hinnes, L.; Huxley, P.;
Pieper, M.; Tschesche, H.; Bode, W. Biochemistry 1995, 34,
14012; (b) Grams, F.; Reinemer, P.; Powers, J. C.; Kleine,
T.; Pieper, M.; Tschesche, H. Eur. J. Biochem. 1995, 228,
830; (c) Campestre, C.; Agamennone, M.; Tortorella, P.;
Prezioso, S.; Biasone, A.; Gavazzo, E.; Pochetti, G.;
Mazza, F.; Hiller, O.; Tschesche, H.; Consalvi, V.; Gallina,
C. Bioorg. Med. Chem. Lett. 2006, 16, 20.
5. Ilies, M. A.; Banciu, M. D. Nonsulfonamide carbonic
anhydrase inhibitors. In Carbonic Anhydrase—Its Inhibi-
tors and Activators; Supuran, C. T., Scozzafava, A.,
Conway, J., Eds.; CRC Press: Boca Raton (FL), USA,
2004; pp 209–242.
6. (a) Mangani, S.; Haakansson, K. Eur. J. Biochem. 1992,
210, 867; (b) Eriksson, A. E.; Kylsten, P. M.; Jones, T. A.;
Liljas, A. Proteins: Struct. Funct. Genet. 1988, 4, 283; (c)
Abbate, F.; Supuran, C. T.; Scozzafava, A.; Orioli, P.;
Stubbs, M. T.; Klebe, G. J. Med. Chem. 2002, 45, 3583; (d)
Supuran, C. T.; Conroy, C. W.; Maren, T. H. Proteins:
Struct. Funct. Genet. 1997, 27, 272.
7. Briganti, F.; Pierattelli, R.; Scozzafava, A.; Supuran, C. T.
Eur. J. Med. Chem. 1996, 31, 1001; (b) Bertini, I.;
Luchinat, C.; Scozzafava, A. Struct. Bond. 1982, 48, 45;
(c) Bertini, I.; Canti, G.; Luchinat, C.; Scozzafava, A.
J. Am. Chem. Soc. 1978, 100, 4873.
8. (a) Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T.
Expert Opin. Ther. Pat. 2004, 14, 667; (b) Supuran, C. T.
Expert Opin. Ther. Pat. 2003, 13, 1545; (c) Supuran, C. T.;Scozzafava, A.; Casini, A. Med. Res. Rev. 2003, 23, 146;
(d) Supuran, C. T.; Scozzafava, A. Expert Opin. Ther. Pat.
2002, 12, 217.
9. (a) Supuran, C. T.; Scozzafava, A. Curr. Med. Chem.-
Immun, Endoc. Metab. Agents 2001, 1, 61; (b) Supuran, C.
T.; Scozzafava, A. Expert Opin. Ther. Pat. 2000, 10, 575;
(c) Pastorekova, S.; Parkkila, S.; Pastorek, J.; Supuran, C.
T. J. Enzyme Inhib. Med. Chem. 2004, 19, 199; (d)
Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Expert
Opin. Ther. Pat. 2006, 16, 1627.
10. (a) De Clercq, E. J. Clin. Virol. 2001, 22, 73; Canestri, A.;
Ghosn, J.; Wirden, M.; Marguet, F.; Ktorza, N.; Boubez-
ari, I.; Dominguez, S.; Bossi, P.; Caumes, E.; Calvez, V.;
Katlama, C. Antiviral Ther. 2006, 11, 561.
11. (a) Biron, K. K. Antiviral Res. 2006, 71, 154; (b) Gross, G.;
Braun, D. Hautarzt 2006, 57, 40.
12. (a) Rusconi, S.; Innocenti, A.; Vullo, D.; Mastrolorenzo,
A.; Scozzafava, A.; Supuran, C. T. Bioorg. Med. Chem.
Lett. 2004, 14, 5763; (b) Winum, J. Y.; Innocenti, A.;
Gagnard, V.; Montero, J. L.; Scozzafava, A.; Vullo, D.;
Supuran, C. T. Bioorg. Med. Chem. Lett. 2005, 15, 1683;
(c) Nishimori, I.; Minakuchi, T.; Onishi, S.; Vullo, D.;
Scozzafava, A.; Supuran, C. T. J. Med. Chem. 2007, 50,
381.
13. (a) Supuran, C. T.; Scozzafava, A. Activation of carbonic
anhydrase isozymes. In The Carbonic Anhydrases—New
Horizons Birkhauser; Chegwidden, W. R., Carter, N.,
Edwards, Y., Eds.; Verlag: Basel, Switzerland, 2000; p 197;
(b) Ilies, M.; Scozzafava, A.; Supuran, C. T. Carbonic
anhydrase activators. In Carbonic Anhydrase—Its Inhibi-
tors and Activators; Supuran, C. T., Scozzafava, A.,
Conway, J., Eds.; CRC Press: Boca Raton (FL), USA,
2004; pp 317–352.
14. Thiry, A.; Dogne´, J. M.; Masereel, B.; Supuran, C. T.
Trends Pharmacol. Sci. 2006, 27, 566.
15. Khalifah, R. G. J. Biol. Chem. 1971, 246, 2561, An
SX.18MV-R Applied Photophysics stopped-ﬂow instru-
ment has been used. Phenol red at a concentration of
0.2 mM has been used as indicator, working at the
absorbance maximum of 557 nm, with 10 mM Hepes,
pH 7.5, as buﬀer, 0.1 M Na2SO4, for maintaining constant
the ionic strength. The CO2 concentrations ranged from
1.7 to 17 mM for the determination of the kinetic
parameters and inhibition constants. For each inhibitor
concentration at least six traces of the initial 5–10% of the
reaction have been used for determining the initial
velocity. The uncatalyzed rates were determined in the
same manner and subtracted from the total observed
rates. Stock solutions of inhibitors were prepared at a
concentration of 10–50 mM (in water) and dilutions up to
0.1 lM done with the assay buﬀer mentioned above.
Inhibitor and enzyme solutions were preincubated togeth-
er for 15 min at room temperature prior to assay (or as
otherwise indicated), in order to allow for the formation of
the E-I complex. Triplicate experiments were for each
inhibitor concentration, and the values reported through-
out the paper are means of such results. The recombinant
CA isozymes have been obtained as previously reported by
our group.12.
16. (a) Temperini, C.; Scozzafava, A.; Vullo, D.; Supuran,
C. T. Chemistry 2006, 12, 7057; (b) Temperini, C.;
Scozzafava, A.; Puccetti, L.; Supuran, C. T. Bioorg.
Med. Chem. Lett. 2005, 15, 5136; (c) Temperini, C.;
Scozzafava, A.; Vullo, D.; Supuran, C. T. J. Med.
Chem. 2006, 49, 3019.
17. (a) Temperini, C.; Scozzafava, A.; Supuran, C. T. Bioorg.
Med. Chem. Lett. 2006, 16, 5152; (b) Parkkila, S.; Vullo,
D.; Puccetti, L.; Parkkila, A. K.; Scozzafava, A.; Supuran,
C. T. Bioorg. Med. Chem Lett. 2006, 16, 3955; (c) Elder, I.;
C. Temperini et al. / Bioorg. Med. Chem. Lett. 17 (2007) 2210–2215 2215Tu, C.; Ming, L. J.; McKenna, R.; Silverman, D. N. Arch.
Biochem. Biophys. 2005, 437, 106.
18. Ferraroni, M.; Tilli, S.; Briganti, F.; Chegwidden, W. R.;
Supuran, C. T.; Wiebauer, K. E.; Tashian, R. E.;
Scozzafava, A. Biochemistry 2002, 41, 6237.
19. hCA I was crystallized at 22 C by the hanging drop vapor
diﬀusion method.18 Drops containing 5 ll of 20-30 mg/ml
hCA I in 100 mM Tris.HCl buﬀer, pH 9.0, were mixed
with 5 ll of precipitant buﬀer (25% (w/v) PEG 4000, LiCl
0.4 M, 10% ethylene glycol in 100 mM Tris–HCl, pH 9.0)
and equilibrated over a reservoir of 1 ml of precipitant
buﬀer. Crystals appeared after 5–6 weeks. The hCA
I-foscarnet complex was prepared by soaking these crystals
in 100 mM Tris–HCl buﬀer (pH 9.0) solution containing
50 mM drug for 1 week. When crystals were maintained in
contact with foscarnet for shorter periods (2h–5 days), no
binding of the drug to the enzyme has been evidenced by
means of X-ray crystallography (data not shown). Crystals
of the adduct were mounted in nylon loop and exposed to a
cold (100 K) nitrogen stream. Diﬀraction data were
collected on a CCD Detector KM4 CCD/Sapphire using
CuKa radiation (1.5418 A˚). The unit cell dimensions were
determined to be a = 62.58 A˚, b = 69.51 A˚, c = 120.44 A˚,
and a = b = c = 90, in the space group P212121. Data were
processed with CrysAlis RED (Oxford Diﬀraction 2006).20
The structure was analyzed by diﬀerence Fourier tech-
nique, using the PDB ﬁle 2FW4 as starting model. The
reﬁnement was carried out with the program REF-
MAC521; the model building and map inspections were
performed using the COOT program.22 The ﬁnal model of
the complex had an R-factor of 24.9% and R-free 31.0% inthe resolution range 20.0–2.0 A˚, with a rms deviation from
standard geometry of 0.014 A˚ in bond lengths and 1.53 in
angles. The correctness of stereochemistry was ﬁnally
checked using PROCHECK.23 Coordinates and structure
factors have been deposited within the Protein Data Bank
(accession code 2IT4). Crystallographic parameters and
reﬁnement statistics are summarized in Table 2.
20. Oxford Diﬀraction, CrysAlis RED. Version 1.171.32.2,
2006, Oxford Diﬀraction Ltd.
21. Jones, T. A.; Zhou, J. Y.; Cowan, S. W.; Kjeldoard, M.
Acta Crystallogr. 1991, A47, 110.
22. Emsley, P.; Cowtan, K. Acta Crystallogr. 2004, D60,
2126.
23. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.;
Thornton, J. M. J. Appl. Crystallogr. 1993, 26, 283.
24. (a) De Simone, G.; Di Fiore, A.; Menchise, V.; Pedone, C.;
Antel, J.; Casini, A.; Scozzafava, A.; Wurl, M.; Supuran,
C. T. Bioorg. Med. Chem. Lett. 2005, 15, 2315; (b) Casini,
A.; Antel, J.; Abbate, F.; Scozzafava, A.; David, S.;
Waldeck, H.; Schafer, S.; Supuran, C. T. Bioorg. Med.
Chem. Lett. 2003, 13, 841; (c) Abbate, F.; Casini, A.; Owa,
T.; Scozzafava, A.; Supuran, C. T. Bioorg. Med. Chem.
Lett. 2004, 14, 217; (d) Kim, C. Y.; Chang, J. S.; Doyon, J.
B.; Baird, T. T.; Fierke, C. A.; Jain, A.; Christianson, D.
W. J. Am. Chem. Soc. 2000, 122, 12125; (e) Whittington,
D. A.; Waheed, A.; Ulmasov, B.; Shah, G. N.; Grubb, J.
H.; Sly, W. S.; Christianson, D. W. Proc. Natl. Acd. Sci.
U.S.A. 2001, 98, 9545.
25. Winum, J. Y.; Temperini, C.; El Cheikh, K.; Innocenti, A.;
Vullo, D.; Ciattini, S.; Montero, J.-L.; Scozzafava, A.;
Supuran, C. T. J. Med. Chem. 2006, 49, 7024.
